Monitor the preliminary prospectus supplement for offering size and pricing. The company's high volatility (23% normal daily move) means even a moderate-sized offering could have outsized price impact. Watch for any subsequent updates on use of proceeds or financial runway.
INO drugs
INO drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $1.22entry
- T+1 · 8d ago +24.28%α +21.91% · $1.51
- T+5 · 4d ago +17.70%α +15.10% · $1.43
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Inovio Pharmaceuticals announced an underwritten public offering of common stock with a 30-day underwriter option for up to 15% additional shares. The offering size and pricing are undisclosed; proceeds will be used for general corporate purposes. This dilutive event comes at a market cap of $172M and high volatility (23% normal daily move).
Key Facts
- Inovio intends to offer shares of common stock in an underwritten public offering
- Underwriters granted a 30-day option to purchase up to 15% additional shares
- Jefferies and Piper Sandler are joint book-running managers
- Offering is subject to market conditions; size and terms not disclosed
- Shelf registration statement filed July 2, 2026 and declared effective July 10, 2026
Financial Impact
Undisclosed amount; market cap is $172M, so any material offering will be dilutive relative to current shares outstanding
Risk Factors
- Offering size and pricing are undisclosed, creating uncertainty about dilution magnitude
- High stock volatility (23% normal daily move) amplifies price sensitivity to offering terms
- Market conditions may prevent completion of the offering on favorable terms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302931327 |
Track record
20 reports on INO
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
- Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago Press Release Bearish 4/10 Viewing Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers